Genmab to Present Data at ASCO Annual Meeting

Copenhagen, Denmark, May 23, 2024 – Genmab (Nasdaq: GMAB) will highlight significant advancements in cancer treatment at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The event, held both in Chicago and virtually from May 31 to June 2, will feature multiple oral and poster presentations of Genmab's innovative clinical programs.

Key Highlights:
1. Epcoritamab:
- Presentations:
- Combination Therapy: A rapid oral presentation will discuss the combination of epcoritamab with rituximab and lenalidomide (R2) in patients with untreated follicular lymphoma (FL).
- Relapsed/Refractory FL: Another rapid oral session will detail findings from the pivotal and cycle 1 dose optimization cohorts of the EPCORE NHL-1 study, focusing on relapsed/refractory FL.
- Diffuse Large B-cell Lymphoma (DLBCL) and FL: Multiple posters will present results from phase 2 trials evaluating subcutaneous administration of epcoritamab in outpatient settings for relapsed or refractory DLBCL and FL, as well as combination therapies with R-DHAX/C and GemOx.

2. Tisotumab Vedotin:
- Head and Neck Cancer: Updated data from the innovaTV 207 trial focusing on pretreated patients with relapsed/metastatic head and neck squamous cell carcinoma will be highlighted in a rapid oral session.
- Cervical Cancer: The innovaTV 301 trial results in patients with recurrent or metastatic cervical cancer post-chemotherapy will be presented in a poster session.

3. Acasunlimab (GEN1046/BNT311):
- Metastatic Non-Small Cell Lung Cancer (mNSCLC): Initial results from a phase 2 trial evaluating acasunlimab as monotherapy and in combination with pembrolizumab in previously treated mNSCLC will be presented in a poster.

Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab, emphasized the relevance of these presentations, noting the progress in developing therapies aimed at improving the lives of cancer patients.

Clinical Evaluation and Future Plans:

- Epcoritamab is an IgG1-bispecific antibody that leverages Genmab's DuoBody® technology. It engages T-cells and B-cells to elicit an immune response targeted at CD20+ cells. Epcoritamab is currently approved in some lymphoma indications in various regions, but not yet for FL in the U.S. or EU. Genmab and its partner, AbbVie, are conducting extensive evaluations of epcoritamab across multiple hematologic malignancies through ongoing phase 3 trials.

- Tisotumab vedotin, co-owned with Pfizer, is an antibody-drug conjugate designed to target tissue factor-expressing cancer cells, leading to cell death. It has received FDA approval for treating recurrent or metastatic cervical cancer but is still under investigation for head and neck squamous cell carcinoma.

- Acasunlimab is a bispecific antibody combining Genmab's and BioNTech’s technologies. It aims to stimulate an antitumor response by activating T cells and natural killer cells upon binding to PD-L1. This drug is in phase 2 development under a collaboration with BioNTech SE.

Virtual Mid- to Late-Stage Pipeline Update:

Genmab will host a virtual review of its mid- to late-stage pipeline data presented at ASCO on June 3. This session will provide insights into the advancements and future direction of Genmab's oncology programs.

About Genmab:

Founded in 1999, Genmab is a global biotechnology company headquartered in Copenhagen, Denmark, with operations in North America, Europe, and Asia Pacific. The company focuses on creating novel antibody therapies to improve the lives of patients with cancer and other serious diseases. By 2030, Genmab aims to revolutionize treatment options with groundbreaking antibody medicines.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!